Verrica's Phase III Success Paves Way For Filing Of New Cantharidin Formulation VP-102
After reporting positive pivotal data for VP-102 in the contagious skin disease molluscum, Verrica is looking forward to a 2020 launch, with plans to price for broad access.
You may also be interested in...
Anticipating a July approval of its cantharidin formulation, Verrica says it is poised to implement a buy-and-bill model for a clinician-administered product with an addressable market of 6 million.
Nitric oxide-releasing SB206 missed the primary endpoint in a pair of Phase III studies, but Novan hopes a third study and success on a secondary endpoint still can lead to filing for approval.
Keeping Track: A Duo Of RTOR Approvals, Thumbs Up For First Oral GLP-1 Treatment, And First Ebola Vaccine Nears US Market
The latest drug development news and highlights from our US FDA Performance Tracker.